Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rapt Therapeutics Inc
(NQ:
RAPT
)
7.900
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
39
Open
7.900
Bid (Size)
7.680 (1)
Ask (Size)
7.900 (1)
Prev. Close
7.900
Today's Range
7.900 - 7.900
52wk Range
6.869 - 27.35
Shares Outstanding
34,358,152
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
April 09, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks to Dump Before They Go to Zero
April 09, 2024
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.
Via
InvestorPlace
Performance
YTD
-67.48%
-67.48%
1 Month
-4.47%
-4.47%
3 Month
-65.79%
-65.79%
6 Month
-31.42%
-31.42%
1 Year
-58.85%
-58.85%
More News
Read More
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
March 11, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023
March 07, 2024
Via
InvestorPlace
RAPT Therapeutics: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 07, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
February 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Rivian Automotive Reports Q4 Loss, Joins Etsy, Lucid Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
February 22, 2024
Via
Benzinga
What's Going On With RAPT Therapeutics Stock On Wednesday?
February 21, 2024
Via
Benzinga
Exposures
Product Safety
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 21, 2024
Via
Benzinga
Stocks Slip Ahead Of Fed Minutes, Nvidia Earnings
February 21, 2024
Via
Talk Markets
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Crude Oil Moves Lower; Summit Therapeutics Shares Plummet
February 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 20, 2024
Via
Benzinga
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 20, 2024
Via
Benzinga
Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today?
February 20, 2024
Via
Benzinga
Exposures
Product Safety
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
February 20, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Dow Dips Over 100 Points; US Leading Economic Index Falls In January
February 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Rebounds; Nasdaq Drops Triple Digits
February 20, 2024
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Nasdaq Down 1%; Capital One Set To Buy Discover
February 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 20, 2024
Via
Benzinga
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
February 20, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
February 13, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
